Post by EQT Group

In 2019, two scientists in Germany set out to solve a problem that had frustrated cancer researchers for decades. Just seven years later, Gilead Sciences agreed to acquire their company for up to $5bn. Tubulis co-founder Dominik Schumacher attributes the EQT-backed company’s rise to a few key principles: a strong belief in the company’s science, an openness to advice from experienced outsiders, and the discipline to adapt to new data. Underpinning all of that was a determination to deliver on the long-held promise of “guided-missile” cancer drugs. Read more by clicking the link in the first comment.